Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Shareholder Meeting (August 2021)
14 slides from Amplia Therapeutics's shareholder meeting presentation, Aug 27, 2021
Slide 1: ASX Release: Annual General Meeting – CEO Presentation
ABN 16 165 160 841 ASX RELEASE 27 August 2021 Annual General Meeting – CEO Presentation Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to release the Chief Executive Officer’s presentation to the Annual General Meeting which is to be held at 12.00 midday today. The Ann
Slide 2: 2021 Annual General Meeting CEO Presentation
2021 Annual General Meeting CEO Presentation 27 August 2021 Amplia Therapeutics Limited
Slide 3: Disclaimer
Disclaimer The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Amplia Therapeutics Limited (“Amplia”) in any jurisdiction. No representation or warranty, express or implied, is made in relation to the a
Slide 4: Company Highlights
Company Highlights Clinical stage company developing small molecule drugs against Focal Adhesion Kinase (FAK) for two, significant disease areas: • Cancer – combination therapy in hard-to-treat solid tumours • Fibrosis – prevention and treatment Phase 1 clinical trial of AMP945 completed • Oral dose
Slide 5: Focal Adhesion Kinase – one drug target, multiple opportunities
Focal Adhesion Kinase – one drug target, multiple opportunities Focal Adhesion Kinase (FAK) Indication FIBROTIC DISEASES SOLID CANCERS • Collagen accumulation • Cell migration and metastasis Biology • Collagen crosslinking • Collagen accumulation • Fibronectin production • Local regulation of immune
Slide 6: Preclinical data supports dual indications
Preclinical data supports dual indications Lung Fibrosis Pancreatic Cancer AMP945 reduces lung fibrosis in widely AMP945 increases survival in aggressive accepted disease model mouse model of pancreatic cancer control – healthy lung bleomycin – fibrotic lung bleomycin + AMP945 5
Slide 7: Amplia's target indications
Amplia’s target indications Idiopathic Pulmonary Fibrosis (IPF) Pancreatic Cancer • Affects 130,000 in the US and ~3M people • 60,000 new diagnosis and 48,000 deaths from worldwide pancreatic cancer in the US each year • Devastating, progressive disease caused by the • Difficult-to-treat cancer that
Slide 8: Amplia's pipeline
Amplia’s pipeline DRUG INDICATION THERAPY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 & APPROVAL AMP945 Pancreatic cancer Combination therapy AMP945 Idiopathic pulmonary Monotherapy fibrosis (IPF) AMP945 Other cancers & Combo/Mono fibrotic diseases therapies AMP886 Cancers & Monotherapy fibrotic disease Cur
Slide 9: The Year in Review
The Year in Review One year ago, Amplia was a preclinical-stage Company Today, Amplia has completed its first clinical study is on the brink of two Phase 2 clinical studies • Pancreatic cancer • Pulmonary fibrosis Main Achievements • Commenced and completed Phase 1 trial of AMP945 • Raised $3.8m to
Slide 10: Preclinical to Phase 2-ready in 12 months
Preclinical to Phase 2-ready in 12 months Preclinical Phase 1 Phase 2 Jane Bell appointed Commenced dosing in as Director Exciting data in Phase 1 trial Established Garvan pancreatic collaboration for cancer model pancreatic cancer Positive data in Phase 2 enabling NASH Model activites on track for
Slide 11: Phase 1 Clinical Trial of AMP945
Phase 1 Clinical Trial of AMP945 Summary of Outcomes • Safe and well-tolerated at all doses tested • No serious adverse events (SAEs) or withdrawals and no identified safety trends • Single ascending doses up to 125mg • Multiple ascending dose (100mg, once daily for 7 days) • No detected food effect
Slide 12: AMP945 – 18-month development plan
AMP945 – 18-month development plan CY2021 CY2022 Activity Q3 Q4 Q1 Q2 Q3 Q4 HREC** filing IND* filing Phase 2 trial – pancreatic cancer Phase 2 trial – pulmonary fibrosis * Investigational New Drug Application – USA ** Human Research Ethics Committee - Australia 11
Slide 13: Upcoming targeted milestones
Upcoming targeted milestones *Q3 2021 • Phase 2 pancreatic cancer trial design complete Q4 2021 • Phase 2 IND-enabling activities complete • Ethics approval for Phase 2 pancreatic cancer trial Q1 2022 • Initiate dosing in Phase 2 pancreatic cancer trial • File IND for AMP945 in pancreatic cancer Q2
Slide 14: ampliatx.com
VANaatelite! Exposing cancer. Enhancing treatment. ampliatx.com
Amplia Therapeutics — Shareholder Meeting (August 2021) on 6ix